Literature DB >> 8865025

Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment.

I Kothbauer-Margreiter1, M Sturzenegger, J Komor, R Baumgartner, C W Hess.   

Abstract

Six patients with Hashimoto thyroiditis (HT) and associated encephalopathy (HE) are described and compared with 14 well-documented cases retrieved from the literature. HE typically affects patients when they are euthyroid and, in an appropriate clinical situation, antithyroid autoantibodies are the main indicators of HE. Since clinical features of HE are unspecific, other aetiologies such as infectious, metabolic, toxic, vascular, neoplastic, and paraneoplastic causes have to be excluded. Our own six cases and those from the literature show that two types of initial clinical presentation can be differentiated: a vasculitic type with stroke-like episodes and mild cognitive impairment in nine patients, and a diffuse progressive type with dementia, seizures, psychotic episodes or altered consciousness in 11 patients. These types may overlap, particularly in the long-term course without treatment. Response to steroids was usually excellent with complete remission in 80%. Eighteen of the 20 patients were women. Characteristic, though unspecific, findings were abnormal EEG (90%) and CSF (80%). Together with quantitative neuropsychological testing, these proved sensitive for monitoring the efficacy of therapy. Conversely, antithyroid autoantibody titres did not correlate with the severity or type of clinical presentation. The link between HE and HT is not clear. A pathogenetic role for antithyroid autoantibodies in the central nervous system seems unlikely.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8865025     DOI: 10.1007/bf00900946

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

1.  Thyroid peroxidase/microsomal antibodies are not identical with thyroid cytotoxic antibodies in autoimmune thyroiditis.

Authors:  U Bogner; P Kotulla; H Peters; H Schleusener
Journal:  Acta Endocrinol (Copenh)       Date:  1990-10

2.  THE MANY FACES OF HYPOTHYROIDISM.

Authors:  J A COLLINS; F E ZIMMER; W J JOHNSON; R H KOUGH
Journal:  Postgrad Med       Date:  1964-10       Impact factor: 3.840

3.  Fits, faints, coma, and dementia in myxoedema.

Authors:  E H JELLINEK
Journal:  Lancet       Date:  1962-11-17       Impact factor: 79.321

4.  Hashimoto's disease and encephalopathy.

Authors:  L Brain; E H Jellinek; K Ball
Journal:  Lancet       Date:  1966-09-03       Impact factor: 79.321

Review 5.  Severely impaired consciousness in myxedema--a review.

Authors:  P C Royce
Journal:  Am J Med Sci       Date:  1971-01       Impact factor: 2.378

6.  Letter: Hashimoto's disease, encephalopathy, and splenic atrophy.

Authors:  E H Jellinek; K Ball
Journal:  Lancet       Date:  1976-06-05       Impact factor: 79.321

7.  [A case of Hashimoto's encephalopathy with a relapsing course related to menstrual cycle].

Authors:  K Ishii; A Hayashi; A Tamaoka; H Mizusawa; S Shoji
Journal:  Rinsho Shinkeigaku       Date:  1993-09

8.  [Incidence of abnormal thyroid function in patients with low titers of thyroid microsomal antibodies].

Authors:  K Notsu; N Oka; H Furuya; Y Kato
Journal:  Nihon Naibunpi Gakkai Zasshi       Date:  1991-06-20

9.  Encephalopathy in compensated Hashimoto thyroiditis: a clinical expression of autoimmune cerebral vasculitis.

Authors:  M Shein; A Apter; Z Dickerman; S Tyano; N Gadoth
Journal:  Brain Dev       Date:  1986       Impact factor: 1.961

10.  Evidence for a potential common T-cell epitope between human thyroid peroxidase and human thyroglobulin with implications for the pathogenesis of autoimmune thyroid disease.

Authors:  S M McLachlan; B Rapoport
Journal:  Autoimmunity       Date:  1989       Impact factor: 2.815

View more
  61 in total

1.  Hashimoto's encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease.

Authors:  M Seipelt; I Zerr; R Nau; B Mollenhauer; S Kropp; B J Steinhoff; C Wilhelm-Gössling; C Bamberg; R W Janzen; P Berlit; F Manz; K Felgenhauer; S Poser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

2.  Hashimoto's encephalopathy: neuropsychological findings.

Authors:  I Mazzù; S Mosti; C Caltagirone; G A Carlesimo
Journal:  Neurol Sci       Date:  2011-10-13       Impact factor: 3.307

Review 3.  Clinical and diagnostic aspects of encephalopathy associated with autoimmune thyroid disease (or Hashimoto's encephalopathy).

Authors:  Gianluca Tamagno; Giovanni Federspil; Giovanni Murialdo
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

4.  Hashimoto encephalopathy: a do-not-miss in the differential diagnosis of dementia.

Authors:  Claire J Creutzfeldt; Roman L Haberl
Journal:  J Neurol       Date:  2005-06-13       Impact factor: 4.849

Review 5.  The neurological disorder associated with thyroid autoimmunity.

Authors:  Franco Ferracci; Antonio Carnevale
Journal:  J Neurol       Date:  2006-06-19       Impact factor: 4.849

Review 6.  Hashimoto's encephalopathy : epidemiology, pathogenesis and management.

Authors:  Ramon Mocellin; Mark Walterfang; Dennis Velakoulis
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  Young-onset dementia.

Authors:  Dulanji K Kuruppu; Brandy R Matthews
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

Review 8.  Immunologically mediated dementias.

Authors:  Michael H Rosenbloom; Sallie Smith; Gulden Akdal; Michael D Geschwind
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

Review 9.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

10.  [Depression in Hashimoto's encephalopathy. Successful treatment of a severe depressive episode with a glucocorticoid as an add-on therapy].

Authors:  C Laske; T Leyhe; G Buchkremer; H Wormstall
Journal:  Nervenarzt       Date:  2005-05       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.